Adult ALL Treatment at Diagnosis (LAL2000)

Gruppo Italiano Malattie EMatologiche dell'Adulto

Status: Completed

Conditions: Leukemia, Lymphocytic, Acute

Treatments: Drug: Vincristin, Daunorubicine, Asparaginase, Methotrexate; Drug: Vincristine

Study type: Interventional

Funder types: Other

Identifiers

NCT00537550

LAL2000

Details and patient eligibility

About

The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.

Sex: All

Ages: 14 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of acute lymphoblastic leukemia (ALL)
• Negative myeloperoxidase stain
• Phenotype T (ALL-T) and B(ALL-B)

Exclusion criteria

• Creatinine > 2.5mg/dL after adequate hydratation
• LVEF <50%
• Presence of documented infections not responding to antibiotic and/or antifungal therapy
• Presence of concomitant malignant diseases
• Absence of any psychological condition that does not allow to intake high doses of cortisone
• Patients who have received any antineoplastic chemiotherapy for more than 5 days
• Patients who have received any steroids for more than 10 days

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)